Cardiff Oncology Details Strong Phase 2 Data for Onvansertib in mCRC, Outlines Registrational Path
Summary
Cardiff Oncology disclosed detailed positive Phase 2 clinical trial results for onvansertib in first-line RAS-mutant metastatic colorectal cancer, showing a 72% objective response rate and favorable progression-free survival trends, and outlined its strategy for a registrational Phase 3 trial.
Key Events
-
Positive Phase 2 Data Detailed
Detailed CRDF-004 trial results for onvansertib in first-line RAS-mutant mCRC showed a 72% confirmed objective response rate (ORR) in the 30 mg arm, a 30% improvement over standard of care (FOLFIRI SoC).
-
Favorable Survival Trends Reported
Median progression-free survival (PFS) has not yet been reached in the onvansertib + FOLFIRI/bev arms, with a compelling hazard ratio of 0.37 (p=0.048) versus standard of care.
-
Registrational Trial Strategy Outlined
The company plans an FDA meeting in H1 2026 to finalize the registrational program, with a Phase 3 trial (CRDF-005) expected to initiate in H2 2026, comparing onvansertib + FOLFIRI/bev to standard of care.
-
No Significant Added Toxicity
The CRDF-004 trial data indicated no significant added toxicity with onvansertib, supporting its safety profile for combination therapy.
Analysis
This 8-K provides critical details of the positive Phase 2 CRDF-004 trial for onvansertib, which were previously only broadly mentioned in the February 24, 2026 8-K. The reported 72% objective response rate and favorable progression-free survival trends in first-line RAS-mutant metastatic colorectal cancer (mCRC) are highly significant, especially for a company that recently disclosed a "going concern" warning in its 10-K filed on February 24, 2026. The clear outline of the registrational Phase 3 trial design and planned FDA meeting in the first half of 2026 provides a concrete path forward for the company's lead asset. This positive clinical development is crucial for addressing the company's financial viability and could significantly impact investor sentiment and future financing prospects.
At the time of this filing, CRDF was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.5M. The 52-week trading range was $1.48 to $4.86. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.